Related Experiment Video
Updated: Aug 12, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
TA90-IC, a new marker for advanced colon cancer
N Habal1, R K Gupta, A J Bilchik
1Roy E. Coats Research Laboratories, John Wayne Cancer Institute at St. John's Health Center, Santa Monica, California 90404, USA.
Annals of Surgical Oncology
|June 23, 2000
Summary
Combining TA90 immune complexes (TA90-IC) with carcinoembryonic antigen (CEA) improves colon cancer detection. This dual marker approach identified 93.6% of advanced colon cancer patients, surpassing individual marker efficacy.
Area of Science:
- Oncology
- Biomarker Discovery
- Clinical Diagnostics
Background:
- Carcinoembryonic antigen (CEA) is a common colon cancer marker but has limited sensitivity, especially in early stages.
- TA90, a 90-kDa glycoprotein found in circulating immune complexes, is present in various tumors but rarely in healthy individuals.
- TA90's potential as a novel tumor-associated antigen for colon cancer diagnosis was investigated.
Purpose of the Study:
- To evaluate TA90-specific circulating immune complexes (TA90-IC) as a potential serum marker for colon cancer.
- To compare the diagnostic performance of TA90-IC with CEA in patients with colon adenocarcinoma.
- To assess the combined diagnostic utility of TA90-IC and CEA.
Main Methods:
- Serum samples from 59 colon adenocarcinoma patients were analyzed for CEA and TA90-IC.
- TA90-IC concentrations were measured using a murine monoclonal antibody-based ELISA.
- A positive TA90-IC value was defined as an optical density > 0.410 at 405 nm.
Main Results:
- TA90-IC showed higher elevation rates (82.9%) compared to CEA (70.2%) in colon cancer patients.
- The combined detection of TA90-IC and CEA identified 93.6% of patients.
- The combination of both markers demonstrated a statistically significant improvement (P < .001) over individual markers.
Conclusions:
- The concurrent use of TA90-IC and CEA enhances the detection of advanced colon cancer, reaching 93.6% sensitivity.
- TA90-IC shows promise as a valuable biomarker for colon cancer diagnosis.
- Further research is warranted to explore TA90-IC's utility in screening and monitoring earlier stages of colon cancer.
